Free tool
FAERS Monitor: Potassium Chloride 0.22% In Dextrose 5% and Sodium Chloride 0.9% In Plastic Container
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019630 or its brand name (Potassium Chloride 0.22% In Dextrose 5% and Sodium Chloride 0.9% In Plastic Container, Dextrose, Potassium Chloride, Sodium Chloride). Reports on generic versions are filed under their own applications.
Reports
43
Serious
31
72% of reports
Hospitalization
9
Death reported
17
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death16
- infusion related reaction4
- product packaging confusion3
- blood potassium increased2
- dyspnoea2
- flushing2
- physical product label issue2
- product label confusion2
- product label issue2
- product selection error2
- vomiting2
- abdominal distension1
- anaphylactic reaction1
- atrial fibrillation1
- atrial flutter1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 17 |
| 2015 | 5 |
| 2016 | 2 |
| 2017 | 4 |
| 2019 | 1 |
| 2021 | 3 |
| 2022 | 5 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,116 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product selection error | 2 | 894.3 | 230.8 | 1,001 |
| physical product label issue | 2 | 824.3 | 212.7 | 923 |
| product packaging confusionSignal | 3 | 605.2 | 203.1 | 1,254 |
| product label confusion | 2 | 167.9 | 43.4 | 186 |
| product label issue | 2 | 144.2 | 37.3 | 159 |
| atrial flutter | 1 | 61.3 | 8.8 | 14 |
| blood potassium increased | 2 | 60.3 | 15.6 | 65 |
| infusion related reactionSignal | 4 | 29.5 | 11.6 | 84 |
| flushing | 2 | 9.6 | 2.5 | 8 |
| deathSignal | 16 | 9.1 | 6.2 | 112 |
| anaphylactic reaction | 1 | 8.9 | 1.3 | 1 |
| atrial fibrillation | 1 | 5.0 | 0.7 | 0 |
| abdominal distension | 1 | 4.7 | 0.7 | 0 |
| vomiting | 2 | 2.1 | 0.5 | 0 |
| dyspnoea | 2 | 1.7 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.